An observational study in Diabetes (DM), Type 2 Diabetes and Obesity (Disorder), sponsored by LMC Diabetes & Endocrinology Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by LMC Diabetes & Endocrinology Ltd. · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · LMC Diabetes & Endocrinology Ltd..
Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 13th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. are open now, in 1 country. Recruiting first, the newest first:
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18+
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18+
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18–80
LMC Diabetes & Endocrinology Ltd. · Sites in Canada
Ages 18–75
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2026.
This study's enrollment of 3,392 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 158 across the 6 interventional studies, 892 across the 8 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
LMC Diabetes & Endocrinology Ltd. is the lead sponsor of 22 studies on the registry; 4 are open to participants now.
2 of the studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07889453LMC Diabetes & Endocrinology Ltd.Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide | 2026-12 |
| NCT07157384LMC Diabetes & Endocrinology Ltd.REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 2 by LMC Diabetes & Endocrinology Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 3,392 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →LMC Diabetes & Endocrinology Ltd. is the lead sponsor of 22 studies on the registry; 4 are open to participants now.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study populations will include adults with T2D prescribed semaglutide (T2D sema cohort) or other AHA (T2D other AHA cohort) including sulfonylurea, DPP4i, and/or SGLT2i, or adults with obesity, defined as BMI equal or greater 27 kg/m2, prescribed semaglutide (obesity sema cohort), who attend an LMC Diabetes \& Endocrinology clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
T2D Cohort:
Obesity Cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with T2D prescribed semaglutide
Drug: Semaglutide (SEMA)
Adults with T2D prescribed antihyperglycemic medication beside semaglutide including sulfonylurea, DPP4i, and/or SGLT2i
Adults with obesity, defined as BMI equal or greater than 27 kg/m2, prescribed semaglutide
Drug: Semaglutide (SEMA)
participants who initiate semaglutide
Change in HbA1c- 3 Years
The primary outcome measure is investigating the change in HbA1c from baseline to 3 years (± 90 days) among adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs
Time frame: Baseline to 3 Years
Change in HbA1c- 1 Year
Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 year
Change in HbA1c- 2 Years
Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Proportion of individuals who achieve HbA1c ≤ 7.0% - 1 Year
comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Proportion of individuals who achieve HbA1c ≤ 7.0%- 2 Years
comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Proportion of individuals who achieve HbA1c ≤ 7.0% - 3 Years
comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in body weight- 1 Year
comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in body weight- 2 Years
comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in body weight- 3 Years
comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Percent body weight loss ≥ 5% - 1 Year
comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Percent body weight loss ≥ 5% - 2 Years
comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Percent body weight loss ≥ 5% - 3 Years
comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Percent body weight loss ≥ 10% - 1 Year
comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Percent body weight loss ≥ 10% - 2 Years
comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Percent body weight loss ≥ 10% - 3 Years
comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Percent body weight loss ≥ 15% - 1 Year
comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Percent body weight loss ≥ 15%- 2 Years
comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Percent body weight loss ≥ 15%- 3 Years
comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in BMI- 1 Year
comparing the change in BMI (kg/m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in BMI- 2 Years
comparing the change in BMI (kg/m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in BMI- 3 Years
comparing the change in BMI (kg/m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in Waist Circumference- 1 Year
comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in Waist Circumference- 2 Years
comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in Waist Circumference- 3 Years
comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in Blood Pressure- 1 Year
comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in Blood Pressure- 2 Years
comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in Blood Pressure- 3 Years
comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in eGFR- 1 Year
comparing the change in eGFR (ml/min1.73m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in eGFR- 2 Years
comparing the change in eGFR (ml/min1.73m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in eGFR- 3 Years
comparing the change in eGFR (ml/min1.73m\^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Proportion of individuals with ≥ 50% decline in eGFR- 1 Year
comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Proportion of individuals with ≥ 50% decline in eGFR- 2 Years
comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Proportion of individuals with ≥ 50% decline in eGFR- 3 Years
comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in uACR- 1 year
comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in uACR- 2 years
comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in uACR- 3 Years
comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in ALT- 1 Year
comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in ALT- 2 Years
comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in ALT- 3 Years
comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in Lipids- 1 Year
comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol \[LDL-C\], high-density lipoprotein cholesterol \[HDL-C\], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in Lipids- 2 Years
comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol \[LDL-C\], high-density lipoprotein cholesterol \[HDL-C\], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in Lipids- 3 Years
comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol \[LDL-C\], high-density lipoprotein cholesterol \[HDL-C\], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 1 Year
comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 2 Years
comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 3 Years
comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Number of non-semaglutide GLP-1-based therapies- 1 Year
comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Number of non-semaglutide GLP-1-based therapies- 2 Years
comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Number of non-semaglutide GLP-1-based therapies- 3 Years
comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in insulin use- 1 Year
comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in Insulin- 2 Years
comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in Insulin- 3 Years
comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Change in TDD of insulin- 1 Year
comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 1 Year
Change in TDD of insulin- 2 Years
comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 2 Years
Change in TDD of insulin- 3 Years
comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts
Time frame: Baseline to 3 Years
Incidence of non-acetylsalicylic acid antiplatelet use
comparing the incidence of non-acetylsalicylic acid antiplatelet use between adults with T2D treated with 1 or more years of semaglutide and adults with T2D treated with 1 or more years of other AHAs in the cardiovascular sub-cohort
Time frame: Baseline to Endpoint
Percent body weight loss ≥ 5%
Comparing the percent body weight loss ≥ 5% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Percent body weight loss ≥ 10%
Comparing the percent body weight loss ≥ 10% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Percent body weight loss ≥ 15%
Comparing the percent body weight loss ≥ 15% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Body Weight
Comparing body weight (kg) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
BMI
Comparing BMI (km/m\^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Waist Circumference
Comparing the waist circumference (cm) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
HbA1c
Comparing HbA1c (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Percent of new onset pre-diabetes
Comparing the percent of new onset pre-diabetes (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Percent of new onset T2D
Comparing the percent of new onset T2D (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Blood Pressure
Comparing blood pressure in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
eGFR
Comparing eGFR (ml/min1.73m\^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 year
uACR
Comparing uACR (mg/mmol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
ALT
Comparing ALT (U/L) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
Lipids
Comparing lipids (triglycerides, LDL-C, HDL-C , total cholesterol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)
Time frame: Baseline to 1 Year
HbA1c
Comparing HbA1c between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Proportion of individuals who achieve HbA1c ≤ 7.0%
Comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Body Weight
Comparing body weight (kg) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Percent body weight loss ≥ 5%
Comparing percent body weight loss ≥ 5% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Percent body weight loss ≥ 10%
Comparing percent body weight loss ≥ 10% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Percent body weight loss ≥ 15%
Comparing percent body weight loss ≥ 15% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
BMI
Comparing BMI (kg/m\^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
eGFR
Comparing eGFR (ml/min1.73m\^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Proportion of individuals with ≥ 50% decline in eGFR
Comparing the proportion of individuals with ≥ 50% decline in eGFR between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
uACR
Comparing uACR (mg/mmol) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
ALT
Comparing ALT (U/L) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups
Time frame: Baseline to Endpoint (3 Years)
Plan to share: No — This is an observational study using data retrieved from a national diabetes registry. IPD will not be shared.
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Sep 2026, 7 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Mar 2026 → Feb 2026, primary completion Apr 2026 → Sep 2026 and completion May 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LMC Diabetes & Endocrinology Ltd.